topotecan has been researched along with Lassitude in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW | 1 |
| Borad, MJ; Curtis, KK; Fitch, TR; Griffin, PP; Hartney, JT; Jewell, RC; Lebowitz, PF; Northfelt, DW; Park, JW | 1 |
| Leath, CA; Phippen, NT | 1 |
| Bélanger, K; Bergeron, J; Burdette-Radoux, S; Cairncross, G; Eisenhauer, E; Forsyth, P; Gertler, S; Ludwin, S; MacDonald, D; Soulières, D; Wainman, N | 1 |
| Adamson, PC; Blaney, SM; Bradfield, S; Franklin, J; Hawkins, DS; Krailo, M; Reaman, G; Whitlock, JA | 1 |
| Gajra, A; Garziano, S; Kirshner, J; Neuman, N; Perry, M; Ready, N; Shah, C | 1 |
| Burris, H; Fields, S; Gerrits, CJ; Hudson, I; Loos, WJ; Planting, AS; Rodriguez, GI; Schellens, JH; van Beurden, V; van den Burg, ME; Verweij, J; von Hoff, DD | 1 |
| Beijnen, JH; Beusenberg, FD; Doyle, E; Hearn, S; Herben, VM; Panday, VR; Richel, DJ; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van der Vange, N | 1 |
| Beckman, RA; Gore, M; Hearn, S; Lane, SR; Ross, G; Rustin, G; Schüller, J | 1 |
| Aalders, JG; Beijnen, JH; Bos, AM; de Vries, EG; Hofstra, LS; Mulder, NH; Rosing, H; van der Zee, AG; Willemse, PH | 1 |
9 trial(s) available for topotecan and Lassitude
| Article | Year |
|---|---|
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult | 2009 |
A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Biological Availability; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Fatigue; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan | 2010 |
A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma.
Topics: Astrocytoma; Fatigue; Humans; Infusions, Intravenous; Oligodendroglioma; Topotecan | 2003 |
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Topics: Adolescent; Adult; Astrocytoma; Child; Child, Preschool; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Neuroectodermal Tumors, Primitive; Neutropenia; Recurrence; Sarcoma; Survival Rate; Thrombocytopenia; Time Factors; Topotecan; Treatment Outcome | 2006 |
A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Survival Analysis; Thrombocytopenia; Time Factors; Topotecan; Vomiting | 2007 |
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Fatigue; Female; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Topotecan; Treatment Outcome | 1998 |
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan | 1999 |
Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.
Topics: Abdominal Pain; Adult; Aged; Alopecia; Antineoplastic Agents; Diarrhea; Fatigue; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Nausea; Ovarian Neoplasms; Survival Analysis; Survival Rate; Time Factors; Topotecan; Treatment Outcome; Vomiting | 2001 |
A phase I and pharmacokinetic study of intraperitoneal topotecan.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Exanthema; Fatigue; Female; Humans; Injections, Intraperitoneal; Metabolic Clearance Rate; Middle Aged; Nausea; Ovarian Neoplasms; Topotecan; Treatment Outcome; Vomiting | 2001 |
1 other study(ies) available for topotecan and Lassitude
| Article | Year |
|---|---|
Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fatigue; Female; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Thalidomide; Topotecan | 2009 |